The first patient was treated with ProTrans in January 2018 and there are presently 4 clinical trials and one follow-up study ongoing. The active pharmaceutical ingredient in ProTrans is mesenchymal stromal cells from umbilical cord tissue. The patent pending selection algorithm is utilized for selection of cells and donors to ensure a drug product with immunomodulary capacity.
“It is a privilege to present NextCell’s impressive clinical trial program”, say Mathias Svahn.
The Andvanced Therapies Congress will bring together 1 200 attendees from across the advanced therapy medicinal product, ATMP industry from pharma, biotech, research, regulatory bodies and start-ups. During the last 2 years the Advanced Therapies Industry has seen great leaps forward in innovation, creative solutions to challenging setbacks, new technologies, interest, and investment.
For more information about NextCell Pharma AB, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, email@example.com.
About NextCell Pharma AB
NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100% of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).